Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
|Videos|November 8, 2021
Factors Associated With Progression-free Survival, Overall Survival in the Treatment of Burkitt Lymphoma
Adam Olszewski, MD, associate professor of medicine in Alpert Medical School at Brown University, discusses the factors associated with progression-free survival and overall survival in the treatment of Burkitt lymphoma.
Advertisement
Pharmacy Times interviewed Adam Olszewski, MD, associate professor of medicine in Alpert Medical School at Brown University, to discuss his SOHO 2021 conference presentation on prognostication and treatment of Burkitt lymphoma in the modern era.
During the interview, Olszewski discussed the factors associated with progression-free survival and overall survival in the treatment of Burkitt lymphoma.
Advertisement
Related to this article
A phase 3 trial shows etentamig boosts response and delays progression in triple-class exposed RRMM.
IRAKLIA shows isatuximab OBI boosts comfort and satisfaction vs IV in multiple myeloma, enabling fast at-home dosing with strong completion.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Long-term CASSIOPEIA Registry results show that daratumumab maintenance supports sustained minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma.
A phase 1/2 analysis found rapid, deep responses with mezigdomide plus elranatamab in patients with relapsed or refractory multiple myeloma, but the small cohort and limited follow-up require cautious interpretation.
At NEIAP 2026, Kelsey Norman, PharmD, walked through how VESALIUS-CV, Lp(a)HORIZON, and CKM guidelines change pharmacist-led lipid care.
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Belzutifan Plus Lenvatinib for Advanced Renal Cell Carcinoma After Immunotherapy
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
4
FDA Approves Insulin Efsitora, Once-Weekly Basal Insulin Injection for Adults With T2D
5